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Abstract
Aims/hypothesis Referred to as CCN, the family of growth
factors consisting of cystein-rich protein 61 (CYR61, also
known as CCN1), connective tissue growth factor (CTGF,
also known as CCN2), nephroblastoma overexpressed gene
(NOV, also known as CCN3) and WNT1-inducible signal-
ling pathway proteins 1, 2 and 3 (WISP1, −2 and −3; also
known as CCN4, −5 and −6) affects cellular growth,
differentiation, adhesion and locomotion in wound repair,
fibrotic disorders, inflammation and angiogenesis. AGEs
formed in the diabetic milieu affect the same processes,
leading to diabetic complications including diabetic reti-
nopathy. We hypothesised that pathological effects of
AGEs in the diabetic retina are a consequence of AGE-
induced alterations in CCN family expression.
Materials and methods CCN gene expression levels were
studied at the mRNA and protein level in retinas of control
and diabetic rats using real-time quantitative PCR, western
blotting and immunohistochemistry at 6 and 12 weeks of
streptozotocin-induced diabetes in the presence or absence
of aminoguanidine, an AGE inhibitor. In addition, C57BL/6
mice were repeatedly injected with exogenously formed
AGE to establish whether AGE modulate retinal CCN
growth factors in vivo.
Results After 6 weeks of diabetes, Cyr61 expression levels
were increased more than threefold. At 12 weeks of
diabetes, Ctgf expression levels were increased twofold.
Treatment with aminoguanidine inhibited Cyr61 and Ctgf
expression in diabetic rats, with reductions of 31 and 36%,
respectively, compared with untreated animals. Western
blotting showed a twofold increase in CTGF production,
which was prevented by aminoguanidine treatment. In mice
infused with exogenous AGE, Cyr61 expression increased
fourfold and Ctgf expression increased twofold in the
retina.
Conclusions/interpretation CTGF and CYR61 are down-
stream effectors of AGE in the diabetic retina, implicating
them as possible targets for future intervention strategies
against the development of diabetic retinopathy.
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Introduction
Diabetic retinopathy is a major complication of diabetes
and a leading cause of blindness [1, 2]. Despite recent
progress in understanding the pathogenesis of diabetic
retinopathy, further research is warranted, as the disease
remains neither preventable nor curable.
Diabetic retinopathy is preceded by an asymptomatic
preclinicalphase,inwhichamicroangiopathydevelopswhich
is characterised by diffusely increased vascular permeabil-
ity and capillary basement membrane thickening, resulting
from excess accumulation of extracellular matrix compo-
nents [3–5]. In later stages of preclinical diabetic retinopathy,
endothelial cell and pericyte loss leads to vascular cell death
and the development of acellular capillaries. Experimental
prevention of basement membrane thickening has been
shown to ameliorate these retinal vascular changes
[6, 7]. Thus in galactose-fed rats, a model of diabetes,
downregulation of fibronectin synthesis partly prevented
retinal basement membrane thickening and also reduced
pericyte and endothelial cell loss [6]. Combined down-
regulation of mRNA levels of the extracellular matrix
components fibronectin, collagen type IV alpha 3 (Col4a3)
and laminin beta 1 (Lamb1) not only prevented increases in
their protein levels, but also reduced vascular leakage in the
retina of rats with streptozotocin-induced diabetes [7]. These
findings suggest that basement membrane thickening is not
just an epiphenomenon of the diabetic state, but may be
instrumental in the progression of sight-threatening diabetic
retinopathy. Modulation of basement membrane thickening
may therefore have a preventive effect on the development
of diabetic retinopathy.
However, the mechanisms leading to diabetes-induced
basement membrane thickening remain largely unknown.
One of the postulated mechanisms is the formation of
AGEs in the diabetic milieu. Inhibition of AGE formation
by aminoguanidine has been shown to protect against
retinal capillary basement membrane thickening [8]. AGE
have also been shown to induce extracellular matrix
synthesis in the diabetic rat kidney. A similar induction of
extracellular matrix synthesis was also shown to be
mediated by connective tissue growth factor (CTGF, also
known as CCN2) [9, 10], a member of the family of
proteins referred to as CCN (for cystein-rich protein 61
[CYR61, also known as CCN1], CTGF and nephroblas-
toma overexpressed gene [NOV, also known as CCN3]).
CTGF leads to accumulation of extracellular matrix by
induction of collagen, fibronectin and laminin synthesis, as
well as decreased proteolysis of extracellular matrix
components as a result of increased production of tissue
inhibitors of metalloproteases (TIMP) [9, 11–18]. Recently,
we observed that Ctgf
+/− mice (lacking one functional allele
for Ctgf) are protected from diabetes-induced basement
membrane thickening of retinal and kidney glomerular
capillaries ([19]; P. Roestenberg, F .A. Van Nieuwenhoven,
R. Verheul et al., unpublished results).
We hypothesised in the present study that AGE-induced
basement membrane thickening observed in the retina is at
least partly mediated by CTGF. To establish the role of
CTGF in the AGE-induced production of vascular base-
ment membrane components and their mediators, we
investigated the effects of aminoguanidine on the levels of
CTGF, the other CCN family members (CYR61, NOV and
WNT1-inducible signalling pathway protein 1, 2 and 3
[WISP1, −2, and −3, also known as CCN4, −5 and −6])
[20–22] and vascular basement membrane-related mole-
cules in the retina of rats with streptozotocin-induced
diabetes, as well as in the retina of mice infused with AGE.
Materials and methods
Animals All animal studies were carried out in accordance
with the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. All experiments
involving rats were reviewed and approved by the ethics
committee for animal care and use of the Free University
Medical Centre, Amsterdam, the Netherlands. All experi-
ments involving mice were carried out in accordance with
British Home Office regulations.
Streptozotocin-induced diabetic rat model Adult Wistar
rats (Charles River, Maastricht, the Netherlands), weighing
approximately 250 g, were randomly divided into three
experimental groups: a control group (n=14), a diabetic
group (n=16) and a diabetic group treated with amino-
guanidine hydrogen carbonate (n=14; Fluka, Buchs, Swit-
zerland). Diabetes was induced by a single i.p. injection of
60 mg/kg streptozotocin (Sigma, St Louis, MO, USA).
Immediately prior to use, streptozotocin was dissolved in
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single i.p. injection of 0.1 mol/l citrate buffer only.
Aminoguanidine was administered from day 1 at a dose
of 1 g/l in drinking water. Serum glucose levels and body
weight were monitored at the start and end of the
experiment. Diabetes was verified by a serum glucose
level >13.9 mmol/l. At 6 weeks, half of the rats were
randomly selected from the three experimental groups and
killed with a lethal dose of pentobarbital sodium (i.p.). At
12 weeks the remaining rats were killed. Eyes from each
rat were rapidly enucleated, one being snap-frozen in liquid
nitrogen and stored at −80°C, while the contralateral eye
was fixed in 4% paraformaldehyde. Additionally, blood
samples were collected and plasma levels of N
ɛ-(carboxy-
methyl)lysine (CML) were measured by stable-isotope
dilution tandem mass spectrometry [23].
In vivo administration of exogenous AGE Female C57BL/6
mice (10–12 weeks old) were randomly assigned to two
groups of equal size and injected i.p. with either native
mouse serum albumin (MSA) or glycoaldehyde-modified
MSA (10 mg/kg) daily for seven consecutive days. At 3–4h
after the final injections, mice were killed, eyes enucleated
and retinas dissected freshly, before being snap-frozen in
liquid nitrogen.
Preparation of AGE-modified albumin The glycoaldehyde-
modified MSA preparation was made according to Nagai
et al. [24]. Following dialysis against PBS, endotoxin was
removed using an endotoxin-removing column (Pierce,
Rockford, IL, USA). Glycoaldehyde-MSA and native
MSA were passed three times through separate columns to
ensure that all contaminating endotoxin was removed.
Analysis of the CML content of glycoaldehyde-MSA and
native MSAwas performed using gas chromatography–mass
spectrometry. The lysine content of the samples was
analysed by cation exchange chromatography and the values
for CML were corrected for lysine loss and expressed as
mmol CML/mol lysine as previously reported [25].
RNA isolation and mRNA quantification Snap-frozen rat
and mouse eyes were allowed to thaw in ice-cold RNAlater
(Ambion, Austin, TX, USA). The anterior chambers of the
eyes were removed and the retinas were carefully dissected.
Total RNA was extracted with TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). The amount of total retinal RNA
isolated was approximately 12 μg per retina (spectropho-
tometric measurements at 260 nm), with no significant
differences between the experimental groups. The integrity
of the RNA samples was verified using an automated
electrophoresis system (Experion; Bio-Rad, Hercules, CA,
USA). All samples had sharp ribosomal RNA bands with
no sign of degradation.
A2 - μg aliquot of total RNA was treated with DNAse I
(amplification grade; Invitrogen) and reverse-transcribed
into first strand cDNA with Superscript II and oligo(dT)
12–18 (Invitrogen).
Details of the primers are given in the Electronic
supplementary material (ESM) (ESM Table 1). Specificity
of the primers was confirmed by a nucleotide–nucleotide
BLAST (http://www.ncbi.nlm.nih.gov/blast/index.shtml)
search. The presence of a single PCR product was verified
by both the presence of a single melting temperature peak
and detection of a single band of the expected size on a 3%
agarose gel.
Real-time quantitative PCR (qPCR) was performed in a
sequence detection system (ABI Prism 5700; Applied
Biosystems, Foster City, CA, USA). For each primer set a
mastermix was prepared consisting of 1× SYBR Green PCR
buffer (Eurogentec, Seraing, Belgium), 3 mmol/l MgCl2,
200 μmol/l each of dATP, dGTP and dCTP, 400 μmol/
l dUTP, 0.5 U AmpliTaq Gold (Eurogentec) and 2 pmol
primers. All cDNA samples were diluted 1:10 and amplified
using the following PCR protocol: 10 min at 95°C, followed
by 40 cycles of 15 s at 95°C and 60 s at 60°C and a melting
program (60–95°C). Relative gene expression was calculated
using the equation: R=E
−Ct, where E is the mean efficiency
of all samples for the gene being evaluated and Ct is the
cycle threshold for the gene as determined during real-time
PCR. All qPCR experiments were performed at least twice.
Real-time qPCR data from the mouse experiments were
normalised using 18S rRNA, which was determined to be
stably expressed in all experimental groups. For the rat
experiments, no suitable housekeeping genes that were not
regulated by the diabetic background could be found.
Therefore, the rat data were normalised using the relative
starting amounts of cDNA, which was determined using a
novel technique recently developed in our laboratory (J. M.
Hughes, I. Klaassen, W. Kamphuis, C. J. F. Van Noorden
and R. O. Schlingemann, unpublished results). In brief,
reverse transcription reactions were carried out in duplicate
with one set of reactions containing the normal dNTP mix
and the parallel set of reactions containing a dNTP mix
with α-
32P-labelled dCTP. From each sample 4 μl of the
α-
32P-labelled dCTP-incorporated cDNA were pipetted on
to separate nitrocellulose filters, which were allowed to air-
dry. After washing with 0.1 mol/l phosphate buffer,
radioactivity of the filters was measured using a scintillation
counter (Beckman Coulter, Fullerton, CA, USA).
Western blotting Protein was isolated from paraformalde-
hyde-fixed retinal tissue as described by Shi et al. [26]. In
brief, retinas were dissected from the 4% paraformalde-
hyde-fixed rat eyes and pooled in 1.5 ml Eppendorf vials in
antigen-retrieval buffer (20 mmol/l Tris, 2% SDS, pH 7).
The pooled samples were then dissociated using a pestle
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Supernatant fractions were collected after centrifugation at
4°C for 15 min at 10,000g. Protein concentrations were
determined with a bicinchoninic acid protein assay kit
(Perbio, Etten-Leur, the Netherlands) and adjusted to
2.5 μg/μl. For SDS-PAGE and western blots, proteins were
separated using 13% mini gels under reducing conditions.
Following gel electrophoresis, proteins were transferred to
a nitrocellulose filter (Whatman Schleicher & Schuell,
Brentford, Middlesex, UK) using a semi-dry transfer cell
(Bio-Rad). At the end of the transfer, the filter was blocked
in blocking buffer (1% non-fat skimmed milk powder, 1%
BSA, 1 mmol/l NaN3 in Tris-buffered saline and 0.05%
Tween) overnight at 4°C while being gently rocked. The
filter was incubated in blocking solution for 2 h at room
temperature, with the relevant antibodies as defined below.
Following three washes in TBS/0.05% Tween-20, the blots
were incubated in blocking solution with horseradish
peroxidase-conjugated goat–anti-rabbit or goat–anti-mouse
antibodies for 1 h at room temp. After extensive washing,
blots were developed using a chemiluminescent kit (Super-
Signal West Pico; Perbio). Filters were exposed to X-ray
film (Kodak-Biomax, Herts, UK).
Primary antibodies (ESM Table 2) were diluted with
0.3% skimmed milk powder in TBS/Tween and horseradish
peroxidase-conjugated goat–anti-rabbit or goat–anti-mouse
(Perbio) was diluted 1:20,000. Intensity of bands was
quantified by densitometry using AlphaEase software
(AlphaInnotech, San Leandro, CA, USA).
Immunohistochemistry Cryostat sections (10-μmt h i c k )
were stained using an indirect immunoperoxidase procedure
as previously described [27]. Primary antibodies are listed
in ESM Table 2. Primary antibody was omitted for negative
controls.Indirectimmunoperoxidasestainingwas performed
using histostaining reagents (Powervision; ImmunoVision,
Daly City, CA, USA) for all sections except those incubated
with the TIMP1 antibody. The TIMP1 sections were
indirectly stained using horseradish peroxidase-labelled
rabbit–anti-goatantibody(P0160;Dako,Glostrup,Denmark).
Statistics CML data were log10 transformed to obtain a
normal distribution. Significant differences (p<0.05) in
glucose and CML plasma levels, and in gene expression
levels among groups were calculated with single ANOVA.
The Bonferroni post hoc test was used to perform pairwise
comparisons of groups.
Results
Glucose and CML levels in control and diabetic rats In-
duction of diabetes and the degree of hyperglycaemia in
streptozotocin-treated rats was established by serum glu-
cose levels (Fig. 1a). Streptozotocin treatment resulted in a
three- to fourfold increase in serum glucose concentration
after 6 and 12 weeks irrespective of aminoguanidine
treatment.
Plasma levels of CML were measured to determine the
efficacy of aminoguanidine treatment. CML plasma levels
were elevated by twofold at 6 and 12 weeks after streptozo-
tocin-treatment (Fig. 1b). Aminoguanidine treatment had no
effect on CML levels at 6 weeks, but at 12 weeks the CML
levels were decreased by approximately 25%.
CCN family gene expression in control and diabetic
rats After 6 weeks of diabetes, Cyr61 mRNA levels in
the diabetic retina were increased by threefold against
control retina. Treatment with aminoguanidine reduced
Cyr61 expression to levels that were not significantly
different from control levels (Fig. 2). CYR61 protein was
mainly localised in the ganglion cell layer (Fig. 3). No
differences in staining patterns were found between
experimental groups.
Ctgf mRNA levels were elevated by twofold at 12 weeks
of streptozotocin-induced diabetes. Aminoguanidine treat-
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Fig. 1 Plasma glucose (a) and CML (b) levels in control and diabetic
rats at 6 and 12 weeks of streptozotocin-induced diabetes. White bars,
control rats; black bars, diabetic rats; cross-hatched bars, diabetic rats
treated with aminoguanidine. *p<0.05 and *** p<0.001 for difference
between experimental and control group. The aminoguanidine group
was only significantly different from the groups with diabetes at
12 weeks (
†p<0.05). The error bars show the standard deviation for
each group
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Western blotting showed a 1.8-fold increase in CTGF
protein levels in the retina of diabetic rats at 12 weeks,
whereas aminoguanidine treatment also prevented this
effect (Fig. 4). CTGF immunostaining was mainly found
in the ganglion cell layer and was more diffuse throughout
the outer plexiform layer, inner nuclear layer and inner
plexifrom layer (Fig. 3). Differences in staining between
experimental groups were not observed.
Wisp1 and Wisp3 mRNA levels were low in retinas of all
groups of rats. The levels never differed more than 1.4-fold
between experimental and control groups. Due to small
standard deviations, significant differences were found
(Fig. 2), but it is doubtful whether these small differences
are biologically meaningful. Nov and Wisp2 mRNA
expression levels were too low to be detected in all groups
of rats.
Expression of transforming growth factor beta 1 and 2 in
control and diabetic rats To determine whether: (1) trans-
forming growth factor beta (TGFB), an upstream regulator
of CTGF production, is induced by diabetes; and (2) this
Fig. 3 Immunohistochemical
staining patterns of a CYR61,
b CTGF and c TIMP1 in control
rat retinas. Intense staining of
CYR61 and CTGF was present
in large cell bodies of the gan-
glion cell layer (GCL) and weak
staining in the inner plexiform
layer (IPL). Intense uniform
immunostaining of TIMP1 was
found in the GCL and weak
staining in the IPL. INL inner
nuclear layer, OPL outer plexi-
form layer, ONL outer nuclear
layer, RCL rod and cones layer,
RPE retinal pigment epithelium.
Magnification: ×150
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Fig. 2 Gene expression of CCN family members. Fold change,
compared with control values, in retinal mRNA levels of CCN family
members in streptozotocin-induced diabetic rats at 6 (white bars) and
12 weeks (cross-hatched bars) after streptozotocin-induction and in
aminoguanidine-treated, streptozotocin-induced diabetic rats at 6
(black bars) and 12 weeks (grey bars) of diabetes. *p<0.05 for
difference between experimental group and control group;
†p<0.05 for
difference between aminoguanidine-treated diabetic group and diabe-
tes-only group Fig. 4 CTGF protein levels in retina of control and diabetic rats. a
Western blots of CTGF and GAPDH as loading control. Samples were
pooled for each group. A prominent band of CTGF protein is present
in the 12-week diabetic group (12D; n=8), whereas protein bands
were similar in all other groups (control rats at 6 [6C; n=6] and 12
[12C; n=8] weeks, diabetic rats at 6 [6D; n=8] weeks and diabetic
rats treated with aminoguanidine at 6 [6AG; n=7] and 12 [12AG;
n=7] weeks). b The blots were quantified by densitometry and
expressed as a ratio of CTGF:GAPDH
Diabetologia (2007) 50:1089–1098 1093induction is prevented by aminoguanidine in rat retina, we
examined the mRNA levels of its two most common
isoforms, Tgfb1 and Tgfb2. Tgfb1 mRNA expression was
decreased by approximately 30% in retina of rats with
diabetes for 6 weeks (Fig. 5). Whether this difference is
biologically relevant remains to be determined. In all other
experimental groups, Tgfb1 and Tgfb2 mRNA levels were
similar to control levels (Fig. 5). Immunohistochemical
analysis of TGFB1 revealed a vascular pattern of staining in
all experimental groups (Fig. 6).
Expression of extracellular matrix molecules in control and
diabetic rats CTGF and CYR61 are known modifiers of
the extracellular matrix. Therefore, we investigated expres-
sion patterns of various extracellular matrix components.
Col4a3 mRNA levels in the rat retina were elevated by
threefold after 6 weeks of diabetes. Aminoguanidine
treatment inhibited this induction of Col4a3 mRNA levels
by 30% (Fig. 7). Lamb1 mRNA levels showed a 1.5-fold
increase in 12-week diabetic rats, which was virtually
unaffected by aminoguanidine treatment. Fibronectin
mRNA levels were not affected by streptozotocin-induced
diabetes. Timp2 mRNA levels were not affected either, but
Timp1 mRNA levels were elevated by 2.5-fold in retina of
12-week diabetic rats, this increase being completely
prevented by aminoguanidine treatment (Fig. 7). Laminin
and fibronectin were localised immunohistochemically in
microvessels in rat retina (Fig. 6). This staining pattern was
similar in all groups. TIMP1 immunostaining was restricted
to the ganglion cell layer in all groups of rats (Fig. 3).
CCN family mRNA expression in control and AGE-treated
mice AGE-treated MSA infusion of mice induced an
increased retinal expression of Cyr61 and Ctgf mRNA by
3.7-fold and twofold, respectively, compared with control
mice (Fig. 8). Wisp1 and Wisp3 mRNA expression was not
affected by AGE-treated MSA infusion (data not shown).
Summary of results In the retina of rats with streptozotocin-
induced diabetes, mRNA levels of the CCN family
members Cyr61 and Ctgf were increased threefold at
6 weeks and twofold at 12 weeks, respectively, whereas
expression of all other CCN family members was not
notably affected. CTGF protein levels in retina were also
elevated twofold at 12 weeks of diabetes. In the amino-
guanidine-treated diabetic rats these increases were partly
counteracted by treatment with this AGE inhibitor. In line
with these findings, treatment of mice with exogenous AGE
induced elevated retina mRNA levels of Cyr61 and Ctgf,
but not of the other CCN family members. In parallel,
mRNA levels of some extracellular matrix components
were also increased in the retina of diabetic rats, an effect
also prevented by aminoguanidine treatment.
Discussion
We present here a comprehensive expression analysis of the
CCN family of fibrosis-inducing cytokines in the retina of
rats with streptozotocin-induced diabetes. Messenger RNA
and protein levels of CYR61 and CTGF, both known to be
capable of modulating the extracellular matrix, were
increased in diabetic rats, whilst the AGE inhibitor amino-
guanidine attenuated these effects of diabetes. We also
found that exogenously administered AGEs are capable of
inducing Cyr61 and Ctgf expression in the adult mouse
retina in vivo. Taken together, these data present evidence
that AGEs are both necessary and sufficient to cause
increased levels of CYR61 and CTGF in the diabetic retina.
Expression of CTGF at the mRNA or protein level has
previously been demonstrated in vivo in normal and
diabetic rat [28] and human retina [29], as well as in
cultured retinal microvascular cells [30] and astrocytes [31].
Our data on CTGF are in agreement with a previously
reported twofold increase in Ctgf expression in the diabetic
rat retina [28]. In our study, immunostaining with a
polyclonal anti-CTGF antibody showed staining in the
ganglion cell layer [28] and diffusely throughout the larger
part of the inner rat retina. In contrast, in a previous study
of the human diabetic retina employing a monoclonal anti-
CTGF antibody, CTGF was detected in microglia and
pericytes in the microvasculature of the inner retina [29].
These varying patterns of CTGF protein distribution may
be species-related or due to differences in specificity of the
antibodies used.
Gene expression analysis was also performed on the
other five known members of the CCN family. We found
Tgfb1 Tgfb2
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Fig. 5 Fold change of Tgfb1 and Tgfb2 expression in diabetic rats at 6
(white bars) and 12 weeks (cross-hatched bars) after streptozotocin-
induction and in aminoguanidine-treated diabetic rats at 6 (black bars)
and 12 weeks (grey bars) after streptozotocin-induction. Tgfb1 was
significantly decreased in the diabetic rats after 6 weeks (*p<0.05 vs
control). This difference was not observed in the aminoguanidine-
treated group at 6 weeks. Tgfb2 expression was not significantly
altered at either time point
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upregulation in the diabetic retina. In addition to CTGF,
this suggests a possible role for CYR61 in the development
of diabetes-related retinal sequelae. The lack of detectable
Nov and Wisp2 expression argues against a role for these
two proteins in normal or diabetic retina. This is in
agreement with a previous study, which demonstrated that
Wisp2 mRNA was not present in tissues of the adult rat
[32]. Expression of Wisp1, which is much less studied but
known to suppress cancer cell growth in vivo [33], was
slightly decreased in diabetic retina, whereas Wisp3, a cell
growth suppressor and inhibitor of angiogenesis [34], was
increased. The significance of these findings remains
unclear, as the functions of the CCN family members are
complex. Still, such opposing actions may be reflective of a
regulatory balance or may indicate that some CCN family
members are redundant, although this is currently not
considered to be the case in other tissues [35].
The role of CTGF in diabetic renal pathology has been
clearly established. CTGF is responsible for mesangial
expansion [36] and increased extracellular matrix deposi-
tion [37, 38] as observed in early stages of diabetic
nephropathy. Therefore, CTGF and/or CYR61 may have a
similar role in diabetic retina and be responsible for the
thickening of microvascular basement membranes observed
in early stages of diabetic retinopathy.
We also therefore examined expression patterns of the
genes encoding several extracellular matrix-related mole-
cules. Expression of the basement membrane component
Col4a3 was found to be increased concomitantly with
Cyr61 expression after 6 weeks of diabetes, an increase
significantly reduced in aminoguanidine-treated diabetic
rats. At 12 weeks of diabetes, Timp1 and Lamb1 expression
demonstrated a concomitant increase with Ctgf, which was
significantly attenuated in the aminoguanidine-treated
group (not statistically significant for Lamb1). These
findings suggest a causal role of AGEs in the diabetes-
induced production of CTGF, CYR61, COL4A3 and
TIMP1 in the retina. Whether increased Lamb1 expression
is also mediated by AGEs remains to be determined.
Fig. 6 Immunohistochemical
staining patterns of TGFB1 (a,
d), laminin (b, e) and fibronectin
(c, f) in retina of control rats (a–
c) and rats 12 weeks after
streptozotocin-induced diabetes
(STZ) (d– f). Immunostaining of
TGFB1, laminin and fibronectin
was confined to the retinal mi-
crovasculature and did not no-
tably differ between control and
streptozotocin sections. Magni-
fication: × 150
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showing that protein and mRNA levels of the ribosomal
protein SA (previously known as laminin receptor 1
[67 kD, ribosomal protein SA]) are upregulated by AGEs
in cultured retinal microvascular endothelial cells [39].
AGE CML plasma levels, used in our study as a marker
of AGE formation in the rat diabetes model, were not
altered at 6 weeks in diabetic rats, making an effect of
AGEs at this time point questionable. However, it should be
noted that CML is merely one of many types of AGE
known to be generated under hyperglycaemic conditions
[40] and that aminoguanidine has been shown to decrease
serum AGE levels in diabetic rats as early as 6 weeks after
diabetes induction [41].
In previous studies in the diabetic rat kidney, Ctgf and
fibronectin gene expression both increased after 32 weeks
of streptozotocin-induced diabetes [10]. These changes
were prevented by aminoguanidine treatment. As AGE
accumulation in the diabetic kidney was prevented by
aminoguanidine, those authors surmised that the anti-
fibrotic effects of aminoguanidine could be at least partially
mediated by a decrease in CTGF expression [10]. Our study
may have been too short to observe an increase of
fibronectin in the diabetic retina, but otherwise our results
are in line with these findings in kidney. Additional studies
will be necessary to further elucidate the ability of CYR61
and CTGF to directly modulate these extracellular matrix
molecules in retinal vascular cells.
TGFB, considered to be the most important fibrotic
factor, has been shown to upregulate CTGF in many cell
types in vitro [42–44] and in vivo [45, 46]. Although our
findings indicate that TGFB production is not increased in
the diabetic retina, a role for TGFB in the observed
upregulation of CTGF cannot be ruled out, as the regulation
of TGFB bioavailability is complicated and not solely
dependent on the level of TGFB production [47].
We have recently demonstrated that vascular endothelial
growth factor (VEGF) increases expression of Ctgf and
Cyr61 in the rat retina in vivo as well as in retinal vascular
endothelial cells in vitro (E. J. Kuiper, J. M. Hughes, I. M.
C. Vogels et al., unpublished results). As AGEs are known
inducers of VEGF in retinal cells [48, 49], it is possible that
the increases in CTGF and CYR61 observed in our animal
models are the result of AGE-induced VEGF.
A major finding of our study was the ability of
aminoguanidine to attenuate the increase in Ctgf expression
observed in the diabetic rat retina. Tikellis et al. [28] have
reported that perindopril, an ACE inhibitor, prevents
increased Ctgf expression in diabetic rat retina [28]. This
suggests that both interventions may affect a common
molecular mechanism leading to the upregulation of CTGF.
As ACE inhibition has been shown to prevent AGE
accumulation in diabetic tissues [50], it is feasible that
inhibition of AGE formation could be a common molecular
mechanism allowing both ACE inhibitors and amino-
guanidine to inhibit the increase of retinal CTGF.
In summary, this study provides the first evidence that,
in addition to CTGF, the CCN family molecules CYR61,
WISP1 and WISP3 play possible roles in the development
of early stages of experimental diabetic retinopathy. At the
very least, these results warrant further study into the
functional aspects of these molecules in the eye, and of how
these aspects pertain to the development of diabetic
retinopathy. Additionally, we demonstrate for the first time
that AGEs directly upregulate both CTGF and CYR61
levels in the retina in vivo and that aminoguanidine inhibits
these diabetes-induced increases. This provides the first
evidence that CTGF and CYR61 are downstream effectors
of AGEs in the diabetic retina and implicates them as
possible targets for future intervention strategies.
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Fig. 7 Gene expression of extracellular matrix components. Fold
change of extracellular matrix gene expression as indicated in diabetic
rats at 6 (white bars) and 12 weeks (cross-hatched bars) after
streptozotocin-induction and in aminoguanidine-treated diabetic rats at
6( black bars) and 12 weeks (grey bars) after streptozotocin-induction.
*p<0.05 for difference between experimental and control group;
†p<0.05 for difference between aminoguanidine-treated diabetic
group and diabetes-only group
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Fig. 8 Relative mRNA levels of Cyr61 and Ctgf in retinas of control
(white bars) and AGE-treated (black bars) mice, depicted as fold
change in comparison with control mice. *p<0.05 for effect of AGE
treatment on Cyr61 and Ctgf mRNA levels
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